Searching…
Identifying factors predictive of discontinuation and/or nonadherence to deutetrabenazine may facilitate the development of personalized support programs that seek to improve outcomes in patients with HD or TD.
The Centers for Medicare & Medicaid Services, also called CMS, is convening this patient-focused roundtable event and others as part of the Medicare Drug Price Negotiation Program. So, the purpose today of this event ...
Shared Solutions, Teva’s patient support program, is your partner from the very beginning of treatment, from starting your prescription to nurse support and financial assistance.
Having a treatment option like Austedo XR that can be taken as 1 pill, once a day (across therapeutic doses) can help improve the patient experience and streamline treatment regimens—helping to improve challenges with...
The proportion of patients with a PDC higher than 80% was also higher in the Austedo group, though the difference was not statistically significant. Further statistical analyses indicated that, within the Austedo grou...
Almost 80% of patients with Huntington's disease (HD) chorea were able to achieve optimal dosing within four weeks with the 4-week Titration Kit in final START study results START study results further support real-wo...
Claassen DO, Ayyagari R, García-Horton V, et al. Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia.
The Austedo Patient Assistance Program helps reduce Rx costs to $80/month. Provides treatment continuity for patients with neurological disorders.
“These data reinforce that in real-world settings the AUSTEDO 4-week Patient Titration Kit enabled patients to titrate to therapeutic AUSTEDO doses with satisfaction, adherence, and effectiveness similar to results de...
Learn about financial assistance options and resources for your patients with Huntington’s disease (HD) chorea. Find health plans using the prescription coverage tool. See Prescribing Information, including Boxed Warning.
